Summary of "Why People Are Disappointed with Astaxanthin"
Scientific concepts, discoveries, and nature/biology phenomena
Astaxanthin as an antioxidant carotenoid
Astaxanthin is presented as a powerful antioxidant, with evidence discussed in areas including:
- Skin
- Eyes
- Inflammation
- Cholesterol
Longevity/lifespan testing in mice via the Interventions Testing Program (ITP)
Earlier (positive) ITP study (about 2 years prior)
- Dosing/timing: Astaxanthin started at 12 months of age
- Achieved dietary concentration: ~1,840 ppm (reported average), despite a headline reference to higher levels
- Outcome: ~12% longer median lifespan in male mice
- Sex effects: Effects were not robust across females, with only a partial/uncertain signal at one site
Newer (negative) ITP study
- Dosing: Lower dose, ~880 ppm
- Timing: Start age varied by group (started earlier or later depending on group)
- Outcome: No lifespan extension
Interpretation offered
- The differing results are attributed mainly to different protocols (dose and timing).
- Sex-specific and dose-specific effects are emphasized:
- Lifespan benefit appeared primarily in males
- Suggests a threshold dose may be required; below it, effects may disappear
Dose feasibility / translational relevance to humans
The mouse-achieved dietary exposures are argued to be far higher than realistic human intake.
Approximate dose conversion described for an 80 kg male:
- Positive mouse exposure
- Estimated human-equivalent intake: ~1.8 g/day
- Compared with common supplements (~12 mg/capsule): ~150 capsules/day
- Described as not achievable via food
- Food feasibility via salmon astaxanthin content
- Salmon astaxanthin given as ~0.4 to 3.8 mg per 100 g
- Implies tens of kilograms per day would be required (infeasible)
Even the lower ITP dose (880 ppm) is argued to correspond to about:
- ~850 mg/day for an 80 kg adult
- ~71 capsules/day (at 12 mg each) Still described as above typical use.
Why the supplement may still be worthwhile: human trial evidence (non-lifespan outcomes)
Skin protection / UV-related oxidative stress mitigation
A 2021 systematic review & meta-analysis of RCTs reported:
- Oral astaxanthin: 2–12 mg/day for 4–16 weeks
- Reported improvements:
- Moisturization: ~10–15%
- Elasticity: ~3–10%
Eye protection against screen-related oxidative stress
A 2025 RCT in children aged 10–14 years reported:
- Dose: 4 mg/day for 84 days
- Outcomes: reduced digital eye strain and improved visual fatigue
Inflammation biomarker improvement (hs-CRP)
A 2020 meta-analysis of clinical trials reported:
- >12 mg/day for >12 weeks: reduced hs-CRP ~19–26%
- Lower doses (<12 mg) or shorter duration (<12 weeks): no effect (as described)
Cholesterol effects
Two meta-analyses are cited:
- 2020 meta-analysis:
- 12 mg/day most consistently increased HDL ~3%
- 2022 meta-analysis:
- ~3.5% decrease in LDL with 4–20 mg/day
Methods or lists mentioned (protocol comparison)
Key methodological drivers emphasized for ITP lifespan studies
- Dose level (achieved dietary concentration)
- Positive study: ~1,840 ppm
- Negative study: ~880 ppm
- Start age / timing
- Positive study: started at 12 months
- Negative study: start age varied by group (earlier or later)
- Sex-specific analysis
- Male mice showed lifespan benefit in the positive study
- Female results were inconsistent across sites
Researchers or sources featured (as named in the subtitles)
- Interventions Testing Program (ITP) (no individual researchers named)
- 2021 systematic review & meta-analysis of randomized controlled trials (no authors named)
- 2025 randomized controlled trial in children aged 10–14 (no authors named)
- 2020 meta-analysis of clinical trials for hs-CRP/HDL (no authors named)
- 2022 meta-analysis of clinical trials for LDL (no authors named)
Category
Science and Nature
Share this summary
Is the summary off?
If you think the summary is inaccurate, you can reprocess it with the latest model.
Preparing reprocess...